Matt Wall (@mattwall.bsky.social)

*Ahem* What I did on my lockdown (part 1). I taught myself the basics of audio production, & recorded a silly song about my favourite imaging modality. I humbly present "The MRI song" in the hope it's a brief distraction from the general hideousness. youtu.be/zfYINee1VA4

Haven't done one of these for quite a while, but I regret to inform you that I've hideously butchered another classic song in the name of making some weak jokes. I present: Psychedelic Therapy: The song. Have a great time at #PS2025 everyone! youtube.com/watch?v=4V2sGw…

Grateful to @m_wall: Human [psychedelic] neuroimaging: fMRI sciencedirect.com/science/articl…

@RCarhartHarris Oh, it's out! Nice. 👍

This extraordinary psychedelic precision functional mapping dataset is now fully/freely available to all! All the info to access & use it in a newly published Nature Scientific Data Resource: rdcu.be/epxe7 Thanks to the incredible team who created it - Subha S, Rick R, Ginger N, Demetrius P, Nick M, to name a few.

Very nice work here...

New in @NatureMedicine: ReSPCT "An international Delphi consensus for reporting of setting in psychedelic clinical trials" by @ChloePronovostM, Kyle Greenway, myself, and many ReSPCT Experts. "The ReSPCT guidelines and accompanying explanatory document provide a new standard for the design and documentation of extra-pharmacological variables in psychedelic clinical research." nature.com/articles/s4159… respctguidelines.com

Our (@GregFonzo and Charlie Nemeroff) commentary on @m_wall's recent paper comparing effects of psilocybin and escitalopram on emotional responses in the brain. psychiatryonline.org/doi/10.1176/ap…

RT @PeterSjostedtH: Very sad to hear that Lady Amanda Feilding has passed. Without her much twenty-first century research on psychədəlics w…

🚨New paper day! 🚨 Led by the super @pSelvaggi, we found that one week of (barely) treatment dose amisulpride or aripiprazole led to reversible increases in striatal volumes on MRI in healthy volunteers 👇 Why does this matter?? … …

Otsuka Signs Joint Research Agreement with Keio UniversityIndustry-academia collaboration for infrastructure development toward the social implementation of psychedelics in Japan ｜News Releases | Otsuka Pharmaceutical Co., Ltd. otsuka.co.jp/en/company/new…

@RCarhartHarris Thanks Robin! 😀

This is a big one. Classic work by @m_wall and co! Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression pubmed.ncbi.nlm.nih.gov/40329640/

🚨New paper alarm🚨 Excited to share our new publication that breaks new grounds for #psychedelic medicine: the first data on #psilocybin’s effects in any neurodegenerative disease, specifically psilocybin for the treatment of #Parkinson's disease! It was a phase 1 feasibility and tolerability study on 12 patients with all the usual limitations of such studies, e.g. lack of control condition. The treatment consisted of 2 psilocybin sessions, the first with 10mg and then a larger 25mg dose 2 weeks later. As usual psilocybin was coupled with therapy. The study's primary objective was to treat the mood dysfunction associated with Parkinson's. We got the usual large and positive treatment effects as other psilocybin trials: three months after the last dose MADRS significantly improved by 9.3 points, corresponding to 1.0 standardized mean difference (SMD; i.e. large effect). Anxiety, as captured by the Hamilton Anxiety Rating Scale, also significantly improved by 3.8 points, corresponding to 0.7 SMD. More surprisingly, Parkinson's symptoms also improved post-psilocybin! We captured Parkinson's with the standard MDS-UPDRS assessment, , and patients significantly improved in all domains at every post-treatment timepoint (!!!) with mostly moderate-to-large effect sizes. Benefits persisted at the 3 months post last dose timepoint. No serious adverse events (AEs) occurred. As expected, most AEs occurred during psilocybin sessions (anxiety, nausea, headache) and were self-resolving and transient. Even better than the paper that we are already running the follow-up phase 2 trial! If you know anyone in the Bay area who could be interested, please let them know: #Studies" target="_blank" rel="nofollow noopener">psychedelics.ucsf.edu/#Studies. Full paper: tinyurl.com/y9rcp7mk Celebrating with @EllenBradleyMD, @thebandlab and the whole @UCSF's @TrPR_Program crew! 🙏🫂❤️

Neuroscience shows neural oscillations sync with music via neural resonance theory. Not just prediction—brain-body dynamics embody musical structure, driving perception. This may amplify psychedelic experiences, resonating with ASC. nature.com/articles/s4158…

🧠 Just out in Nature: A human brain map of mitochondrial diversity. A powerful collaboration with Mosharov and @MitoPsychoBio. Big step toward bridging cell biology and neuroimaging! 🔗 nature.com/articles/s4158… 🧬 #MitoBrainMap #neuroscience

Visualizing Effective Connectivity in the Human Brain Preprint: biorxiv.org/content/10.110… Code: github.com/ComaRecoveryLa… YouTube video: youtu.be/V0hqs-noYNg Download video & figures: zenodo.org/records/149748… Led by #XanderAtalay & #TeoFecchio @MGH_CNTR @MGHMartinos @MGHNeuroICU

@neurodelia @lisaxiaolu @Imperial_PRG Amazing! Congratulations Lisa!

Congrats to @lisaxiaolu for a successful PhD defence leading our extended DMT studies at @Imperial_PRG . Very proud to call her my first completed PhD student and in awe of how she managed to meticulously carry out some of the most extreme studies one could think of

Beyond happy to share this study with you - Ashley and the team have really exceeded all expectations. Computational modelling of drug effects on multi-domain interoception!

New paper with @Matt_Nour , @tobypill , and Phil Cowen discussing different ways of thinking about and developing psychopharmacological treatments biologicalpsychiatryjournal.com/article/S0006-…

My column on Donald Trump’s “peace plan” for Ukraine theguardian.com/commentisfree/…